- Home
- BCV vs LCTX Comparison
BCV vs LCTX Comparison
Compare BCV & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCV
- LCTX
- Stock Information
- Founded
- BCV 1971
- LCTX 1990
- Country
- BCV United States
- LCTX United States
- Employees
- BCV N/A
- LCTX N/A
- Industry
- BCV Finance/Investors Services
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCV Finance
- LCTX Health Care
- Exchange
- BCV Nasdaq
- LCTX Nasdaq
- Market Cap
- BCV 92.7M
- LCTX 95.2M
- IPO Year
- BCV N/A
- LCTX N/A
- Fundamental
- Price
- BCV $17.52
- LCTX $0.48
- Analyst Decision
- BCV
- LCTX Strong Buy
- Analyst Count
- BCV 0
- LCTX 5
- Target Price
- BCV N/A
- LCTX $4.20
- AVG Volume (30 Days)
- BCV 26.3K
- LCTX 879.3K
- Earning Date
- BCV 01-01-0001
- LCTX 05-13-2025
- Dividend Yield
- BCV 8.13%
- LCTX N/A
- EPS Growth
- BCV N/A
- LCTX N/A
- EPS
- BCV N/A
- LCTX N/A
- Revenue
- BCV N/A
- LCTX $9,499,000.00
- Revenue This Year
- BCV N/A
- LCTX N/A
- Revenue Next Year
- BCV N/A
- LCTX $232.66
- P/E Ratio
- BCV N/A
- LCTX N/A
- Revenue Growth
- BCV N/A
- LCTX 6.19
- 52 Week Low
- BCV $14.09
- LCTX $0.37
- 52 Week High
- BCV $18.11
- LCTX $1.40
- Technical
- Relative Strength Index (RSI)
- BCV 61.13
- LCTX 52.76
- Support Level
- BCV $16.62
- LCTX $0.37
- Resistance Level
- BCV $17.39
- LCTX $0.51
- Average True Range (ATR)
- BCV 0.35
- LCTX 0.04
- MACD
- BCV 0.16
- LCTX 0.00
- Stochastic Oscillator
- BCV 96.05
- LCTX 73.64
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.